Endologix (ELGX) Posts Q4 Loss of $0.26/Share; Reaffirms FY19 Revenue Forecast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results
February 25, 2019 4:01 PM ESTIRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (the Company) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December31, 2018.
Global revenue in the fourth quarter of 2018 was $34.7 million, a 21.2% decrease from $44.0 million in the fourth quarter of 2017. For the year ended December31, 2018, global revenue was $156.5 million, a 13.6% decrease from $181.2 million a year ago.
Our performance in the fourth quarter and second half of the year reinforces confidence in our strategic planning process and our ability to implement improvements. The... More
